Diaceutics (LON:DXRX) Founder & CEO, Peter Keeling, and CFO, Nick Roberts, present full year results for the period ended 31 December 2021. Diaceutics who are a diagnostic commercialisation company for precision testing, have transitioned to a recurring revenue model, and progressed further in the period than anticipated at the beginning of the year. These results show revenue increased 10% to £13.9m. Gross profit increased 13.4% to £10.7m. With a gross margin of 77%. Adjusted EBITDA was £2.3m and profit before tax £0.5m. Net cash £19.7m. Going forward they are focused on expanding their service offering, partner network and data repository to serve the diagnostic commercialisation needs both within and outside of oncology.
Peter Keeling, Founder & CEO
00:17 – Introduction
01:59 – Overview of Diaceutics
02:54 – Overview of the period
04:37 – A transformative year
07:17 – Strategic roadmap
08:18 – Customer needs
09:38 – DXRX Platform
10:16 – Our products
11:34 – Our data
12:24 – Why Diaceutics wins
13:41 – ESG
Nick Roberts, CFO
14:47 – Financial KPIs
16:53 – Income statement
18:01 – Revenue and margin growth
20:19 – Cash position
22:38 – Transition of business
Peter Keeling, Founder & CEO
23:33 – Why invest in Diaceutics
24:30 – Outlook
